5AM Ventures — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Nerissa Kreher(Executive Officer)Kory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNathan Dowden(Executive Officer)Natarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in
Board seatKush M Parmar· per SEC Form D
Co-investorsMPM BioImpactRoche Venture FundTCG CrossoverAgent Capital
BiotechCambridge, US
JOSH MANDEL-BREHM(Executive Officer, Director)RICHARD YOUNG(Director)
BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)inAMIR NASHAT(Director)in
Board seatAndrew J. SchwabAndy Schwab· per SEC Form D · filed Jun 2022
Co-investorsAndreessen HorowitzLongwood FundPolaris Partners
Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for patients with autoimmune diseases.
BiotechHealthtechSan Diego, US
Jennifer Bush(Executive Officer)Yong-Jun Huh(Director)Thomas J. Farrell(Executive Officer)Yu-Kyeong Hwang(Director)Fred Aslan(Executive Officer, Director)Jason Litten(Executive Officer)
Board seatBrian Daniels· per SEC Form D
Co-investorsEcoR1 CapitalRA CapitalvenBio PartnersvenBio Global Strategic
BiotechPleasanton, US
Bill W. Colston, Ph.D.(Director)Klint Rose, Ph.D.(Chief Scientific Officer)Barney E. Saunders,Ph.D.(Chief Executive Officer)Steve Reichenbach(Chief Financial Officer)Joseph J. Victor(Executive Chairman of the Board of Directors)Juan G. Santiago(Executive Officer, Director, Promoter)
Board seatJoseph J. Victor· per SEC Form D
Co-investorsCota CapitalRoche Venture Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.